Down 3.6% today with small-cap biotech stocks: 13 of 17 are down, 2.0% on average; the S&P 500 is down 0.5%.
Lags the market
Down 47% over five years while the S&P 500 rose 76%.
Follow NUVB's trial news. Pro members can get an alert when Nuvation Bio files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Operating cash flow -$121M on $170M of sales |
| Latest filing | 10-Q, Aug 6 |
TodayWith its group.
Thu Nov 12: 31st Annual Meeting of the Society…Industry event · date confirmed.
After its last 4 reports it closed -6.6% on average, higher 1 of 4 times.
$661M in cash
Chief Scientific Officer Gary Hattersley sold 100,000 shares on Aug 19, under a planned sale. 7 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Below Averagefor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means
NUVB is #132 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 132 |
Reports Wed Nov 4, after the close (in 2 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The increase is primarily due to a $3.6 million increase in product supply, and a $1.8 million increase in royalty revenue, offset by a $0.5 million decrease in research and development service revenue.”
NUVB's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase was primarily due to $4.6 million increase in third-party costs related to clinical trial expense offset by a $1.3 million decrease in personnel costs as the prior period included a one-time stock-based compensation charge for performance-based awards that vested upon U.S. FDA approval of taletrectinib.”
From its results filing (SEC filing · Aug 6)
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 6, 2026 | -4.9% | -4.1% | +0.8% |
| May 4, 2026 | -0.9% | +9.5% | +7.9% |
| Mar 2, 2026 | -17.6% | -25.3% | -19.0% |
Sales grew in 2025, to $62.9M. It lost money in both years.
One insider bought $118K across 1 filing in the last 6 months. No open-market sales on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: NUVB is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
“The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products.”
NUVB scores 0 today, which Breakaway calls Below Average. It is #132 of 291 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 47% over five years while the S&P 500 rose 76%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
NUVB scores 0 today, which Breakaway calls Below Average (0 to 5). That is #132 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind NUVB's 0.
One insider bought $118K across 1 filing in the last 6 months. No open-market sales on record. The newest is Robert Mashal, Director, who bought $118K on Jun 9.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.